Pharmaceuticals UAE

UAE Schizophrenia Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

UAE Schizophrenia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UAE · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $40.3 Mn Placeholder estimate
Estimate 2025 $42.6 Mn 0.5% of the global market
Projected 2034 $70.8 Mn 66.1% Adds $28.2 Mn over 9 forecast years
CAGR 2025–2034 5.8% Faster than 14% of 180 Pharmaceuticals markets here
Key players 5
  • UAE is 0.48% of the global market.
  • In Middle East, the largest is Saudi Arabia at $148.5 Mn.
  • Fastest growing: Saudi Arabia at 6.8% a year.
  • UAE ranks 2nd of 2 by size in Middle East.

Market size projection

UAE

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$28.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Schizophrenia Drugs Market market size by year, UAE
YearMarket sizeChange that yearSince 2025
2024 (estimate) $40.3 Mn — —
2025 (base) $42.6 Mn +$2.3 Mn —
2026 (forecast) $45.1 Mn +$2.5 Mn +5.8%
2027 (forecast) $47.7 Mn +$2.6 Mn +11.9%
2028 (forecast) $50.5 Mn +$2.8 Mn +18.4%
2029 (forecast) $53.4 Mn +$2.9 Mn +25.3%
2030 (forecast) $56.5 Mn +$3.1 Mn +32.6%
2031 (forecast) $59.8 Mn +$3.3 Mn +40.3%
2032 (forecast) $63.3 Mn +$3.5 Mn +48.4%
2033 (forecast) $67.0 Mn +$3.7 Mn +57%
2034 (forecast) $70.8 Mn +$3.9 Mn +66.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $8.82 Bn
  2. North America $4.03 Bn
  3. US $3.24 Bn
  4. APAC $1.84 Bn
  5. Europe $1.46 Bn
  6. Canada $737.6 Mn
  7. China $684.8 Mn
  8. Japan $634.9 Mn
  9. Germany $344.5 Mn
  10. Latin America $357.1 Mn
  11. Middle East $337.3 Mn
  12. Brazil $249.2 Mn
  13. Italy $239.0 Mn
  14. France $233.6 Mn
  15. UK $219.3 Mn
  16. Ecuador $172.2 Mn
  17. Spain $162.4 Mn
  18. India $159.9 Mn
  19. Africa $153.7 Mn
  20. Saudi Arabia $148.5 Mn
  21. Mexico $126.7 Mn
  22. New Zealand $98.7 Mn
  23. Australia $94.4 Mn
  24. Russia $85.6 Mn
  25. South Africa $57.8 Mn
  26. UAE (this report) $42.6 Mn
  27. Egypt $25.4 Mn
  28. Philippines $17.8 Mn
  29. Hong Kong $16.4 Mn
  30. Malaysia $12.5 Mn
  31. Singapore $10.5 Mn
  32. Thailand $9.4 Mn
  33. Kenya $5.5 Mn

Report snapshot

UAE Schizophrenia Drugs Market Analysis at a glance
Market size, 2025$42.6 Mn placeholder estimate
Forecast, 2034$70.8 Mn placeholder estimate
Growth (CAGR), 2025–20345.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersJohnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Teva Pharmaceutical, AbbVie Inc. (see all)
Regulator in the UAEEDESource: Emirates Drug Establishment. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UAE Schizophrenia Drugs Market Analysis Executive Summary

Schizophrenia drugs control symptoms such as hallucinations and delusions, including long-acting injectables and new non-dopamine medicines.

Key segments of the schizophrenia Drugs market include drug class (Second-Generation Antipsychotics, Long-Acting Injectables and Muscarinic Agonists) and route (Oral and Injectable).

Bar chart: UAE Schizophrenia Drugs market size, 2024–2034, placeholder estimates. $40.3 Mn in 2024, $42.6 Mn in 2025 and $70.8 Mn in 2034, 5.8% CAGR.
UAE Schizophrenia Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UAE Schizophrenia Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the schizophrenia Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the schizophrenia Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the schizophrenia Drugs market.

Competitive Landscape for Schizophrenia Drugs Market in UAE

The schizophrenia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Schizophrenia Drugs Market in UAE

Schizophrenia Drugs in the UAE: rules, payment and health figures

The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medicines from the Ministry of Health and Prevention.⁠[1] Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate.⁠[2] Suicide rate: 2.9 per 100,000 people in 2023, the latest WHO figure for the UAE.⁠[3]

[1] Emirates Drug Establishment. Checked 14 Nov 2026.

[2] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for schizophrenia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UAE.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Schizophrenia Drugs right now, from free public sources.

Latest research 16,702 papers since 2021 (worldwide)

  1. Systems pharmacology and translational insights into herbal therapeutics for schizophrenia: Mechanistic advances, network-based approaches, and future directions. Journal of pharmacological sciences, 2026
  2. Editorial: Using Early Improvement to Guide Antipsychotic Treatment in Adolescent Schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2026
  3. Synergy between Gq and Gi proteins for the antipsychotic-like effects of mGlu2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2026
  4. Are we moving forward from amisulpride? LB-102 (N-methyl amisulpride) in acute schizophrenia. Expert opinion on investigational drugs, 2026
  5. Posterior-lateral basal forebrain cholinergic nuclei hypoconnectivity in the inferior frontal cortex is associated with verbal fluency deficits in schizophrenia. Schizophrenia (Heidelberg, Germany), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Schizophrenia Drugs in context

The UAE compared

  • Suicide rate: 2.9 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 3rd highest of the 9 countries we cover in Middle East.[1]
  • Health spending per person: 2,402 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 9 countries we cover in Middle East.[2]
  • Doctors: 2.99 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 3rd highest of the 9 countries we cover in Middle East.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Schizophrenia Drugs market in the UAE?
Placeholder estimate: about $42.6 Mn in 2025, rising to about $70.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Schizophrenia Drugs market in the UAE growing?
Placeholder estimate: about 5.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Schizophrenia Drugs market report cover?
The report splits the market by drug class (Second-Generation Antipsychotics, Long-Acting Injectables, Muscarinic Agonists, First-Generation Antipsychotics), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Schizophrenia Drugs market?
Key players include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Teva Pharmaceutical and AbbVie Inc..
What is driving the Schizophrenia Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the schizophrenia Drugs market. Governments and employers are investing more in mental health care.
Who regulates Schizophrenia Drugs in the UAE?
The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medicines from the Ministry of Health and Prevention. Source: Emirates Drug Establishment. Checked 14 Nov 2026.
How is healthcare paid for in the UAE?
Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate. Source: Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
What does WHO report for the UAE?
Suicide rate: 2.9 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the UAE are 65 or older?
1.8% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on Schizophrenia Drugs?
PubMed lists 16,702 papers on Schizophrenia Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Schizophrenia Drugs in UAE? Our analysts can size it for your plan. Talk to us See the public data Suicide rate for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in UAE

See all
Same topic, other categories

Related on mental health

See the topic